We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · November 01, 2022

A Decision Support Tool to Identify Patients With Ulcerative Most Likely to Benefit from Vedolizumab vs Adalimumab

Inflammatory Bowel Diseases

 

Additional Info

Disclosure statements are available on the authors' profiles:

Inflammatory Bowel Diseases
Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab
Inflamm. Bowel Dis. 2022 Oct 03;28(10)1555-1564, PS Dulai, ECL Wong, W Reinisch, JF Colombel, JK Marshall, N Narula

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading